Merck’s KEYTRUDA® (pembrolizumab) Approved in Japan for Three New First-Line Indications Across Advanced Renal Cell Carcinoma (RCC) and Recurrent or Distant Metastatic Head and Neck Cancer

Off #MRK, Corporate News, Health, Health Information, Human Health, Latest News, Life Sciences, Medicine, Merck, Merck Pharmaceutical, NYSE:MRK, Oncology, Oncology Newsroom, Pharmaceuticals, Prescription Medicine News, Science and Health, Science and Research

Dateline City:
KENILWORTH, N.J.

KEYTRUDA Now Approved for Six Cancer Types Plus Microsatellite Instability-High (MSI-H) Tumors in Japan

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck’s anti-PD-1 therapy, received new approvals from the Japan Pharmaceuticals and Medical Devices Agency (PMDA) in advanced renal cell carcinoma (RCC) and head and neck cancer for the following additional indications in Japan:

Language:
English

Contact:

Media:
Pamela Eisele
(267) 305-3558

Ayn Wisler
(917) 691-6218

Investors:
Peter Dannenbaum
(908) 740-1037

Michael DeCarbo
(908) 740-1807

Ticker Slug:
Ticker:
MRK

Exchange:
NYSE

@Merck

read more

Read Original Article: Merck’s KEYTRUDA® (pembrolizumab) Approved in Japan for Three New First-Line Indications Across Advanced Renal Cell Carcinoma (RCC) and Recurrent or Distant Metastatic Head and Neck Cancer »

About The Author